The Medical Advisor

Muscle Mass Is a Key to Longevity  Dr Gabrielle Lyon and Dr Joseph Mercola both strongly believe muscle-centric medicine is part of the solution for many chronic health problems, including obesity, yet very little attention is given to it. "Obesity, Alzheimer's diabetes and cardiovascular disease actually begin in skeletal muscle, years before they become apparent," she says. "Obesity, diabetes, these are diseases of skeletal muscle insulin resistance. But what's so shocking is that everyone is focused, especially in the medical community, on attacking obesity, as opposed to fixing the underlying problem, which is really augmenting skeletal muscle and optimizing muscle with nutrition, which is primary, and training, secondary." As explained by Lyon, while there's certainly benefit to cardiovascular exercise — mitochondrial biogenesis, for example — resistance ...

The medical landscape of 2026 has been defined by the mass adoption of GLP-1 receptor agonists (Semaglutide, Tirzepatide). While the cardiovascular benefits are undeniable, a silent crisis has emerged: Rapid Musculoskeletal Decline. If you are losing weight but losing your "frame," you aren't getting healthier—you are getting smaller. This guide provides the clinical protocol for protecting your bone density and muscle mass while on GLP-1 therapy. 1. The 2026 Clinical Reality: Weight Loss vs. Musculoskeletal Health Recent data from the American Academy of Orthopaedic Surgeons (AAOS) indicates that GLP-1s may affect musculoskeletal health. Specifically, GLP-1 Receptor Agonists may be associated with improved short-term postoperative benefits, alongside possible long-term risks of osteoporosis, gout and osteomalacia compared with non-users. Rapid weight loss reduces the mechanical loading on your skeleton. Without this stress, bone resorption (bre...